DOCSLIB.ORG

A Compound for Use in Imaging Procedures Original Research Article

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Compound for Use in Imaging Procedures Original Research Article J of Nuclear Medicine Technology, first published online September 3, 2015 as doi:10.2967/jnmt.115.162404 A compound for use in imaging procedures Original research article Mulugeta Semework, Ph.D., Postdoctoral Research Scientist Columbia University Department of Neuroscience 1051 Riverside Drive, Unit 87 New York, N.Y. 10032 e-mails: [email protected] [email protected] Tel: 678-362-3554, Fax: 646-774-7649 Sources of support: NINDS training grant from 2T32MH015174-35 (to Dr. Rene Hen); Support from NEI grant 1 R01 EY014978-06 (to Dr. Michael E. Goldberg); Supplement grant through NEI grant 3 R01 EY014978-06; Brain & Behavior Research Foundation (NARSAD) 2013 Young Investigator Award; generous scan time, technical and expert support from New York State Psychiatric Institute MRI unit, PET Center at Columbia University Medical Center Department of Radiology, Department of Radiology of the Center for Neurobiology and Behavior, of Columbia University/Neurological Institute and the radiology department of NY- Presbyterian Hospital. Word count: 5073 (including references) Short running title: Imaging compound 1 Abstract Numerous research and clinical interventions, such as targeted drug deliveries or surgeries, finding blood clots, abscess, lesions, etc., require accurate localization of various body parts. Individual differences in anatomy make it hard to use typical stereotactic procedures that rely upon external landmarks and standardized atlases. For instance, it is not unusual to make misplaced craniotomies in brain surgery. This project was thus carried out to find a new and easy method to correctly establish the relationship between external landmarks and medical scans of internal organs, such as specific brain regions. METHODS This paper introduces an MRI, CT scan and X-ray visible compound (composition) that can be applied to any surface and therefore provide an external reference point to an internal (eye-invisible) structure. RESULTS Tested in non-human primates and isolated brain scans, this compound showed up with the same color in different scan types, making practical work possible. Conventional, and mostly of specific utility products such as contrast agents, are differentially colored or completely fail to show up, and are not flexible. CONCLUSION This composition can be made with different viscosities, colors, odor, etc. It can also be mixed with hardening materials such as acrylic for different uses, such as for industrial/engineering objectives. Laparoscopy wands, electroencephalogram (EEG) leads, etc. could also be embedded with or surrounded by the compound for ease in 3D visualizations. A pending US patent (IR# CU13187) endorses this invention. 2 Keywords— Structural MRI, CT-scan, X-ray, imaging compound, neurosurgery. 3 I. INTRODUCTION Medical and engineering practices constantly employ the use of devices and methods for visualizing internal structures in humans, animals, machines, etc. Three very well established imaging methods, magnetic resonance imaging (MRI), computed tomography (CT) and X-ray are commonly employed. Recently, integrated Positron emission tomography (PET) magnetic resonance (PET/MR) systems have been getting attention and are currently being used in the clinic to measure motion with high temporal resolution (1) without additional instrumentation. The question still remains, how can one externally register a MRI, CT, or X-ray identified internal body part with those visible to the naked eye? For instance, where should a surgeon make a precise 2 cm skin incision to remove a bone outgrowth which is only 1 cm wide, if that is all he needs? With its increased ease, power and accessibility, especially the high resolution of T1-weighted structural images (2), MRI continues to be the choice medical imaging technique. There has been a growing interest in using this tool to study brain structure, function, development, and pathologies (3). However, unresolved technical and scientific difficulties, such as lack of means to scan and visualize certain objects, make it difficult to match up interest with success. These problems are critical especially when one considers surgery on vital structures such 1 as the brain, as anatomy differs despite similarities in organization and relative location with respect to each other. There is variability between individuals in pattern of brain area folding, shape and size of cortical areas and relative locations (4). It is not uncommon to make a misplaced craniotomy when standardized atlases are used for localization of subcortical neural regions (5). Since MRI is a non-invasive method that capitalizes on the complex mosaic across the cortical sheet (4), and since it permits the visualization of the neural structure of the brain in vivo (5), it is possible to solve much of this problem by taking individual MRIs pre-surgery and mapping structures of interest to an external marker and using established coordinates during surgery. This invention aims at contributing to such a solution by expanding on a recent knowledge gained from preliminary research on non-human primates. It also builds upon an old method developed for expressing relationships between surface markers, such as tattoos on head skin and underlying major brain structures (6). The previous (old) method mentioned above used a common practice of land marking to form a mathematical mapping with internal structures of interest. Skin tattoos (outside markers) were identified in MRI scans from vitamin E tablets affixed to the skin overlaying the tattoos. This posed three major problems for a wider use: 1) Vitamin E doesn’t show up equally and clearly in CT and X-ray scans and several MRI sequences, such as T1, T2 and flairs. 2) The tablets are not flexible and sizable to affix to different external body parts which are not always straight or easily 2 accessible. 3) Not all external body parts that are accessible and straight allow reliable contact (stickiness) with the tablets. The aforementioned problems call for a flexible, sizable and safe substance which can be used in, if not all, several MRI sequences and other scanning methods. This paper introduces such a substance, an imaging compound which is not available in the market. II. MATERIALS, METHODS AND PRELIMINARY RESULTS To replicate common problems, such as Vitamin E and Gd showing up only on certain scans and conditions, data from both the starting development process and the final stages are presented in this and the main results section. In short, the compound has been tested in monkey MRI, and fixed monkey brain CT scans and X-rays and it has been found to have well delineated radio density. It has not been clinically tested. For all experiments, there was no human subjects used and therefore no need for Institutional Review Board approval. The Animal Care and Use Committees at Columbia University and the New York State Psychiatric Institute (NYSPI) approved all protocols as complying with the guidelines established in the Public Health Service Guide for the Care and Use of Laboratory Animals. Figure 1 shows initial testing results in brief. The ingredients and the final mix were separately packed into different compartments of a small multi-pocketed plastic pouch. The compound (mix) is the only formulation which shows up more or 3 less equally and clearly in T1, T2 and T2 flair MRI scans (see Table 1 for parameters for all MRI sequences). In general laboratory research practices, non-human primate skulls are routinely covered with a dental acrylic (cement), either to protect a craniotomy or to secure a head-posting structure. Being an ‘inert’ structure, the dental acrylic cannot be seen in any MRI scan. Using the compound however, its outlines can now be visualized. This allows the acrylic mound to be used in planning future surgeries, or following up of any process and objects inside it, or inside the brain (Figure 2). By extension, the compound can be put over any body part, such as the skin over a patient’s chest, neck, etc. and the scan results can be used to plan interventions. Since ultimately clinical utility will be the greatest target, the final MRI testing of this product was performed in a setting which resembles common medical practices in two ways. One: MRI scanning sequences with parameters used in patient evaluation procedures, including T1, T2, fast-spin echo (FSE), Fractional anisotropy, single-shot FSE (SSFSE), three-dimensional Fast Spoiled Gradient Echo (3D-FSGPR), etc. were implemented. Two: a number of small vinyl tubes filled with the compound were glued to a plastic helmet (a swimming cap that mimics EEG caps, as shown in Figure 3), and the aforementioned scans were acquired. This is to demonstrate one possible use: a multi-purpose wearable landmark that can be imaged overlaying body parts (brain structures for instance). Shown in Figure 3 are the results from an assortment of scans of the compound in a network of surgical tubes glued to a plastic cap covering a phantom/dummy brain. Note that the scans that do not show the compound clearly 4 are where diffusion and anisotropy are imaged, ones that are not the most widely used in the clinic. However, the seemingly negative results in Figure 3 were mostly because the parameters for all the scans have not been optimized at this stage. Further refinement (of the MR methods and the chemistry of the compound) resulted in more positive results (subsequent figures). The compound’s constitution was modified for the second round of testing, which aimed at further ascertaining the preliminary results and including other MRI sequences and scan types (CT and X-ray). The main ingredients and their proportions (by volume) are: 1) distilled water/Betadine: 30- 45%, as solvents and bright T2-weighted MR images; 2) vitamin E oil: 15-20%; 3) purified butter: 5-10%; 4) Olive Oil (slightly warmed) 5-10%; 5) other materials specific to project particulars (up to 15%). Based on desired consistency and purpose, the percentage of the ingredients can be modified to make the compound.
Load more

Recommended publications
  • Medical Instruments/Equipment Catalogue
    MEDICAL INSTRUMENTS/EQUIPMENT CATALOGUE Addis Ababa, Ethiopia December, 2008 WHO Ethiopia 1 TABLE OF CONTENTS Page No. Acknowledgements ………………………………………………..II Forward…………………………………………………………….III Introduction………………………………………………………..IV Diagnostic Instruments…………………………………………….1 Laboratory instruments……………………………………............14 Imaging instruments………………………………………………..30 General Surgery instruments………………………………………..32 ENT instruments……………………………………………………55 Ophthalmic instruments……………………………………………..73 Cardiovascular and thoracic instruments..………………………….110 Dental instruments…………………………………………………131 Orthopedic instruments……………………………………………..148 Rectal instruments…………………………………………………..175 Gynecology instruments…………………………………………….179 Physiotherapy ………………………….……………………………196 Hospital Equipments…………………………………………………203 Catalogue index………………………………………………………210 i ACKNOWLEDGEMENTS The Pharmaceutical Fund and Supply Agency (PFSA) of Ethiopia would like to extend its gratitude to the World Health Organization (WHO) for its technical support and for meeting all the financial expenses associated with the preparation and printing of this Catalogue. PFSA acknowledges the contribution of Sister Mebrat Ashine (from PFSA), Mr Bekele Tefera (National Professional Officer for Essential Drugs and Medicines policy of WHO office) and Mr Ashenafi Hussein (from PFSA) who jointly prepared this catalogue with great commitment and effort. PFSA also thanks all those who contributed directly or indirectly for the preparation of this catalogue. ii F0RWARD The day to day health care activities
    [Show full text]
  • Molecular Imaging of Inflammatory Disease
    biomedicines Review Molecular Imaging of Inflammatory Disease Meredith A. Jones 1,2, William M. MacCuaig 1,2, Alex N. Frickenstein 1,2, Seda Camalan 3 , Metin N. Gurcan 3, Jennifer Holter-Chakrabarty 2,4, Katherine T. Morris 2,5 , Molly W. McNally 2, Kristina K. Booth 2,5, Steven Carter 2,5, William E. Grizzle 6 and Lacey R. McNally 2,5,* 1 Stephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA; [email protected] (M.A.J.); [email protected] (W.M.M.); [email protected] (A.N.F.) 2 Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA; [email protected] (J.H.-C.); [email protected] (K.T.M.); [email protected] (M.W.M.); [email protected] (K.K.B.); [email protected] (S.C.) 3 Department of Internal Medicine, Wake Forest Baptist Health, Winston-Salem, NC 27157, USA; [email protected] (S.C.); [email protected] (M.N.G.) 4 Department of Medicine, University of Oklahoma, Oklahoma City, OK 73104, USA 5 Department of Surgery, University of Oklahoma, Oklahoma City, OK 73104, USA 6 Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA; [email protected] * Correspondence: [email protected] Abstract: Inflammatory diseases include a wide variety of highly prevalent conditions with high mortality rates in severe cases ranging from cardiovascular disease, to rheumatoid arthritis, to chronic obstructive pulmonary disease, to graft vs. host disease, to a number of gastrointestinal disorders. Many diseases that are not considered inflammatory per se are associated with varying levels of inflammation.
    [Show full text]
  • Scintillator Requirements for Medical Imaging
    Lawrence Berkeley National Laboratory Lawrence Berkeley National Laboratory Title Scintillator requirements for medical imaging Permalink https://escholarship.org/uc/item/5pc245ds Author Moses, William W. Publication Date 1999-09-01 eScholarship.org Powered by the California Digital Library University of California Accepted by the International Conference on Inorganic Scintillators and Their Applications: SCINT99 LBNL-4580 Scintillator Requirements for Medical Imaging* William W. Moses Lawrence Berkeley National Laboratory, University of California, Berkeley, CA 94720 USA Scintillating materials are used in a variety of medical imaging devices. This paper presents a description of four medical imaging modalities that make extensive use of scintillators: planar x-ray imaging, x-ray computed tomography (x-ray CT), SPECT (single photon emission computed tomography) and PET (positron emission tomography). The discussion concentrates on a description of the underlying physical principles by which the four modalities operate. The scintillator requirements for these systems are enumerated and the compromises that are made in order to maximize imaging performance utilizing existing scintillating materials are discussed, as is the potential for improving imaging performance by improving scintillator properties. Keywords: Medical Imaging, Planar X-Ray, X-Ray CT, SPECT, PET 1. Introduction The first medical image is arguably the x-ray image that Röntgen took of his wife’s hand in 1895. While Roentgen used photographic film to convert the x-rays into a form observable by the human eye, within one year powdered phosphor materials such as CaWO4 replaced photographic film as the x-ray conversion material [1, 2], and have been an integral part of medical imaging devices ever since.
    [Show full text]
  • Radiology in the Next Hundred Years Alexander R
    26 World Health • 48th Yeor, No. 3, Moy-J une 1995 Radiology in the next hundred years Alexander R. Margulis f we review the for brain tu­ accomplish­ mours, while I ments of interventional imaging during radiology is the last 100 years making advances since Rontgen's with the intro­ discovery of duction of X-rays, we must catheters through conclude that the femoral progress was artery to carry initially slow but radiotherapy to gained speed, an affected with momentous organ. Indeed advances in interventional technology. The radiology, which relatively early in the beginning breakthroughs used only fluo­ were the image roscopy with Coronary angiography examination. A radiation-opaque dye injected into the body outlines intensifier and arteries and shows up any obstruction on the screen. television view- television view­ ing for imaging ing, which made interventional control, is today also employing radiology possible and transformed ultrasound, CT and now magnetic gastrointestinal fluoroscopy into an To be able to prosper in the resonance imaging. objective, detailed, data-gathering future, medical imaging must discipline. Radiology benefited from continue to decrease in the spin-off of space exploration and . Threat to progress Cold War defence technology, result­ mvasJVeness, mcrease m ing in breakthroughs in computers, The explosive progress in imaging, electronics, the move from tubes to sensitivity and specificity and however, has also coincided with the transistors to printed circuits on general rise in the cost of medicine, boards to silicone chips, miniaturiza­ - more than anything else - producing a reaction which is threat­ tion, telecommunications and fine­ remain affordable and ening further progress.
    [Show full text]
  • RIDER Database Resource: Plans for a Public-Private Partnership
    RIDER Database Resource and Plans for a Public-Private Partnership Table of Contents 1. RIDER Database: Executive Summary. 1.1 RIDER Goals 1.2 Progress Report and time lines for future plans 1.3 Clarification of the Goals of the Federal Trans-Agency Oncology Biomarker Qualification Initiative (OBQI) and the RIDER Project 2. Introduction: Goals of the White Paper. 3. Clinical and Historical Background 3.1 Lung Cancer 3.2 RECIST Criteria 4. RIDER Pilot Project: Progress Report (2004-06). 4.1 Goals of the Pilot Project 4.2 Initial Development of Image Archive (caBIG) 4.3 Data Transfer Strategies: (RSNA: MIRC) 4.4 Initial Progress on Data Collection 4.5 RIDER: Progress on Boundary Identification of Nodules: 4.6 RIDER Support for RIDER Pilot for FY 06 4.7 NCI-NIBIB supported FDA Fellowship and visiting scientists. 4.8 NIST Collaboration on Imaging Standards 5. RIDER: Plans for the Demonstration Project 5.1 Imaging Data Collection: Acquisition Parameters 5.2 Populating the Database: Case Selection Criteria 5.3 Rider Database Design: Initial Research plans. 5.4 Multi Site Project Infrastructure 5.4.2 Process Model 5.4.3 Validation Software Tools 5.5 Meta Data and Data Management Tools 5.5.1 Multi Site Process Model 5.5.2 Interoperability with CaBIG 5.3.3 Patient Confidentiality 5.6 Standardized Methods for Software Performance 5.7 Engagement and Scientific Role of Industry Stake Holders 5.7.1 Potential Image Date Sources: Industry Drug Trials 5.7.2 Correlation of change Analysis Data with Clinical Outcome 5.7.3 Device and Software Industry: Acceptance of Standards.
    [Show full text]
  • US5322682.Pdf
    ||||||||||||| US005322682A United States Patent (19) 11 Patent Number: 5,322,682 Bartzokis et al. (45) Date of Patent: Jun. 21, 1994 54 METHOD FOR QUANTITATIVELY "Dashed Hopes for MRImaging of the Head and Neck MEASURING AND MAPPING STORED . ." Editorials from the Neuroradiology Section, RON IN TSSUE USING MRI Dept. of Radiology, Hospital of the University of Penn (75) Inventors: George Bartzokis; Carolanne K. sylvania, Radiology 1991; 184:25-26. Phelan, both of Los Angeles, Calif. "T-Relaxometry-A Critical Investigation . ," Thomas Tolxdorff et al., SMRM 1988, p. 33. 73 Assignee: The Regents of the University of "T2 Values in the Human Brain: Comparison with California, Oakland, Calif. Quantitative Assays of Iron and Ferritinl' Julian C. (21) Appl. No.: 926,245 Chen, M.D. et al. Radiology 1989, pp. 521-526. "Field Strength in Neuro-MRImaging: A Comparison 22 Filed: Aug. 6, 1992 of 0.5T and 1.5T' Clifford R. Jack, Jr., et al., Journal of 51) Int. Cl...................... G01N 24/08; A61K 33/26; Computer Assisted Tomography, vol. 14, No. 4, 1990, GO1V 3/00 pp. 505-513. 52 U.S. C. ..................................... 424/9; 128/653.2; (List continued on next page.) 128/653.4; 436/173; 324/300; 324/307; 324/308; 424/646 Primary Examiner-Glennon H. Hollrah 58) Field of Search ................. 424/9, 646; 128/653.2, Assistant Examiner-Gary E. Hollinden 128/653.4, 654; 436/173; 324/300, 307, 308 Attorney, Agent, or Firm-Daniel L. Dawes (56) References Cited U.S. PATENT DOCUMENTS (57) ABSTRACT 4,477,777 10/1984 Gordon ............................... 324/300 The invention provides a specific measure of iron stores 4,735,796 4/1988 Gordon ..................................
    [Show full text]
  • Nuclear Magnetic Resonance Imaging Technology: a Clinical, Industrial, and Policy Analysis
    Nuclear Magnetic Resonance Imaging Technology: A Clinical, Industrial, and Policy Analysis September 1984 NTIS order #PB85-146207 — HEALTH TECHNOLOGY CASE STUDY 27: Nuclear Magnetic Resonance Imaging Technology A Clinical, Industrial, and Policy Analysis SEPTEMBER 1984 This case study was performed as a part of OTA’s Assessment of Federal Policies and the Medical Devices Industry Prepared for OTA by: Earl P. Steinberg, M. D., M.P.P. Assistant Professor, Johns Hopkins School of Medicine and John Hopkins School of Hygiene and Public Health; Senior Associate, Office of Medical Practice Evaluation; also w/Henry J. Kaiser Family Foundation Faculty Scholar in General Internal Medicine and Alan B. Cohen, Sc.D. Associate Director, Center for Hospital Finance and Management; also w/Assistant Professor of Health Policy and Management, Johns Hopkins School of Hygiene and Public Health f I OTA Case Studies are documents containing information on a specific medical technology or area of application that supplements formal OTA assessments. The material is not normally of as immediate policy interest as that in an OTA Report, nor does it present options for Congress to consider. CONGRESS OF THE UNITED STATES Office of Technology Assessment Washington, D C 20510 Recommended Citation: Health Technology Case Study 27: Nuclear Magnetic Resonance Imaging Technology: A Clinical, Industrial, and Policy Analysis (Washington, DC: U.S. Congress, Office of Tech- nology Assessment, OTA-HCS-27, September 1984). This case study was performed as part of OTA’s assessment of Federal Policies and the Medical Devices Industry. Library of Congress Catalog Card Number 84-601123 For sale by the Superintendent of Documents, U.S.
    [Show full text]
  • Ultrasound.Pdf
    Ultrasound J. Cornwall, Chair H. Abarbanel W. DaIly S. FIatte R. Westervelt May 1996 JSR-95-145 Approved for Public Release. Distribution Unlimited. DTIC QUALITY llJSPEOTED a JASON The MITRE Corporation 1820 Dolley Madison Boulevard Mclean, Virginia 22102-3481 (703) 883-6997 Form Approved REPORT DOCUMENTATION PAGE OMB No. 0704·0188 Public reporting burden for this collection of Information estimated to average t hour per response, Including the time for review Instruellons, searc hlng existing data sources, gathering and maintaining the data needed, and complellng and reviewing the collection of Information. Send comments regarding this burden estimate or any other aspect of this coIleellon 01 Information, Including suggestions for reducing this burden. to Washington Headquarters Services. Directorate for Information Operalions and Reports, 1215 Jefferson Davis Highway. Sulle 1204. Arlington, VA 22202·4302. and to the Office of Management and Budget. Paperwork Reduellon ProJeel (0704'()188). Washington, DC 20503. 1. AGENCY USE ONLY (Leave blank) 12. REPORT DATE r' REPORT TYPE AND DATES COVERED May 1996 4. TITLE AND SUBTITLE S. FUNDING NUMBERS ULTRASOUND 6. AUTHOR(S) 07-95-8534-A4 H. Abarbanel, J. Cornwall, W. Dally, S. Flatte, R. Westervelt 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER The MITRE Corporation JASON Program Office, Z561 1820 Dolley Madison Blvd JSR-95-145 McLean, Virginia 22102 9. SPONSORINGIMONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORINGIMONITORING AGENCY REPORT NUMBER DARPA/TIO 3701 North Fairfax Drive, Arlington, Va 22030-1714 JSR-95-145 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION/AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE Approved for Public Release.
    [Show full text]
  • Micro-Imaging of the Mouse Lung Via MRI Wei Wang Washington University in St
    Washington University in St. Louis Washington University Open Scholarship All Theses and Dissertations (ETDs) 5-24-2012 Micro-imaging of the Mouse Lung via MRI Wei Wang Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/etd Recommended Citation Wang, Wei, "Micro-imaging of the Mouse Lung via MRI" (2012). All Theses and Dissertations (ETDs). 733. https://openscholarship.wustl.edu/etd/733 This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Department of Physics Dissertation Examination Committee: Jason Woods, Chair Joseph Ackerman Mark Conradi David Gierada Kenneth Kelton Dmitriy Yablonskiy Micro-imaging of the Mouse Lung via MRI by Wei Wang A dissertation presented to the Graduate School of Arts and Sciences of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy May 2012 Saint Louis, Missouri Abstract Quantitative measurement of lung microstructure is of great significance in assessment of pulmonary disease, particularly in the earliest stages. Conventional stereological assessment of ex-vivo fixed tissue specimens under the microscope has a long and successful tradition and is regarded as a gold standard, but the invasive nature limits its applications and the practicality of use in longitudinal studies. The technique for diffusion MRI-based 3He lung morphometry was previously developed and validated for human lungs, and was recently extended to ex-vivo mouse lungs.
    [Show full text]
  • Clefs CEA N°62
    No. 62 clefsAutumn 2014 Exploring the brain No. 62 Autumn 2014 clefs Exploring the brain 3 Foreword, 5 The complexity of the nervous by Gilles Bloch system: a challenge for neuroscience, by Philippe Vernier Exploring the brain I. NON-INVASIVE EXPLORATION OF THE BRAIN Clefs CEA No. 62 – AUTUMN 2014 6 Introduction, by Denis Le Bihan Main cover picture Representations of 38 bundles of cerebral white matter (one colour per bundle) taken 8 Cerebral imaging: from the first in vivo atlas of human brain a never-ending story, connections. Each one is an assembly of by Denis Le Bihan, images acquired from 78 subjects in the CONNECT/Archi neuroimaging database, Claude Comtat, which was set up at NeuroSpin, using Virginie van Wassenhove cross-sections that are sagittal (vertical; and Isabelle Texier the sections scan the subject from left to right), coronal (vertical; the sections 9 Magnetoencephalography, scan the subject from front to back) and by Virginie van Wassenhove transversal (horizontal). D. Duclap, B. Schmitt, A. Lebois, 10 Positron emission tomography P. Guevara, D. Le Bihan, J.-F. Mangin, 17 C. Poupon/CEA-NeuroSpin 13 Optical imaging, by Anne Planat-Chrétien, Inset top: MIRCen histology platform. Brain Vincent Poher, 18 Very low field detectors, slices marked by different specific Jean-Marc Dinten by Myriam Pannetier-Lecœur indicators are being examined with a and Isabelle Texier microscope. C. Dupont/CEA 14 Magnetic resonance imaging 22 The FLI imaging research bottom: Preparation of a infrastructure, by Régine Trébossen radiopharmaceutical in a shielded hot 17 Looking to the future, and Franck Lethimonnier cell in the Frédéric Joliot Hospital Service (SHFJ).
    [Show full text]
  • 1 ∗A Novel TOF-PET MRI Detector for Diagnosis and Follow up Of
    ∗A novel TOF-PET MRI detector for diagnosis and follow up of the prostate cancer F. Garibaldi1,2,*, S. Beging9, R. Canese3, G. Carpinelli3, N. Clinthorne4, S. Colilli1,2, L. Cosentino5, P. Finocchiaro5, F. Giuliani1,2, M. Gricia1,2, M. Lucentini1,2, S. Majewski6, E. Monno7, P. Musico8, F. Santavenere1,2, J.Tödter9, H. Wegener9, K. Ziemons9 1. INFN Roma Piazzale Aldo Moro 1 – Rome - Italy 2. ISS - National Center of Innovative Technologies for the Public Health - Viale Regina Elena 299 – 00161 – Rome – Italy 3. ISS - Cell Biology and Neurosciences Department-Rome - Viale Regina Elena 299 – 00161 – Rome – Italy 4. Div. Nuclear Medicine / Dept. Radiology, University of Michigan, Ann Arbor, Michigan, USA 48109-5610 5. INFN LNS – Vis S. Sofia 62 – 95125 Catania 6. University of Virginia, Charlottesville, Virginia, USA 7. ENEA- Centro ricerche di Brindisi – S.S. 7 Appia km 706,00 - 72100 Brindisi 8. INFN Genova – Via Dodecaneso 33 - 16146 Genova - Italy 9. FH Aachen University of Applied Sciences Heinrich-Mußmann-Strasse 1 52428 Jülich | Germany Abstract Prostate cancer is the most common disease in men and the second leading cause of death from cancer. Generic large imaging instruments used in cancer diagnosis have sensitivity, spatial resolution, and contrast inadequate for the task of imaging details of a small organ such as the prostate. In addition, multimodality imaging can play a significant role merging anatomical and functional details coming from simultaneous PET and MRI. Indeed, multi-parametric PET/MRI was demonstrated to improve diagnosis, but it suffers from too many false positives. In order to address the above limits of the current techniques, we have proposed, built and tested, thanks to the TOPEM project funded by Italian National Institute of Nuclear Phisics a prototype of an endorectal PET-TOF/MRI probe.
    [Show full text]
  • Nuclear Magnetic Resonance Imaging Technology: a Clinical, Industrial, and Policy Analysis
    Nuclear Magnetic Resonance Imaging Technology: A Clinical, Industrial, and Policy Analysis September 1984 NTIS order #PB85-146207 — HEALTH TECHNOLOGY CASE STUDY 27: Nuclear Magnetic Resonance Imaging Technology A Clinical, Industrial, and Policy Analysis SEPTEMBER 1984 This case study was performed as a part of OTA’s Assessment of Federal Policies and the Medical Devices Industry Prepared for OTA by: Earl P. Steinberg, M. D., M.P.P. Assistant Professor, Johns Hopkins School of Medicine and John Hopkins School of Hygiene and Public Health; Senior Associate, Office of Medical Practice Evaluation; also w/Henry J. Kaiser Family Foundation Faculty Scholar in General Internal Medicine and Alan B. Cohen, Sc.D. Associate Director, Center for Hospital Finance and Management; also w/Assistant Professor of Health Policy and Management, Johns Hopkins School of Hygiene and Public Health f I OTA Case Studies are documents containing information on a specific medical technology or area of application that supplements formal OTA assessments. The material is not normally of as immediate policy interest as that in an OTA Report, nor does it present options for Congress to consider. CONGRESS OF THE UNITED STATES Office of Technology Assessment Washington, D C 20510 Recommended Citation: Health Technology Case Study 27: Nuclear Magnetic Resonance Imaging Technology: A Clinical, Industrial, and Policy Analysis (Washington, DC: U.S. Congress, Office of Tech- nology Assessment, OTA-HCS-27, September 1984). This case study was performed as part of OTA’s assessment of Federal Policies and the Medical Devices Industry. Library of Congress Catalog Card Number 84-601123 For sale by the Superintendent of Documents, U.S.
    [Show full text]